February 20, 2012
1 min read
Save

Survivorship of tapered uncemented hip stems 85% at 22 years

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SAN FRANCISCO – Survivorship of tapered uncemented hip stems at 22 years was 85% in a study presented at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting here.

“There are few data on uncemented stems which are clinically used more than 20 years of follow-up,” Marcus Streit, MD, said during his presentation. “There are few evidence on the impact and survival of uncemented stems in the long term.”

Streit and his team retrospectively reviewed 354 total hip arthroplasties using grit-blasted, tapered femoral stems. The average follow-up was 22 years and average age was 57 years. Outcome measures included Kaplan-Meier survivorship analysis and multivariate analysis using Cox’s regression model with the endpoint of aseptic loosening of the femoral component using risk factors of age, male gender, diagnosis, canal fill index, type of acetabular component and cup revision.

Kaplan Meier analysis revealed 85% survival at 22 years with any type of femoral revision as the endpoint. The researchers found 93% survival with femoral revision for aseptic loosening as the endpoint. Of the 354 patients, 126 patients died by final follow-up and 42 hips required revision. Age, male gender, implant type and diagnosis were not statistically significant.

“Radiographic evaluation shows encouraging results at 20 [years] to 25 years,” Streit said.

Reference:
  • Streit M, Merle C, Innmann M, Gotterbarm T, et al. Long term (20-25 year) results of an uncemented tapered femoral stem and factors affecting survivorship. Paper #356. Presented at the American Academy of Orthopaedic Surgeons 2012 Annual Meeting. Feb. 7-11. San Francisco.
  • Disclosure: Streit has no relevant financial disclosures.

Twitter Follow OrthoSuperSite.com on Twitter